Eric Topol
In 2025, Keytruda (pembrolizumab) was the number one drug for global sales ~$32 billion, targeting PD-1, for cancer immunotherapy. But we didn't know precisely how it works until today @ScienceMagazine https://www.science.org/doi/10.1126/science.adt9365 https://www.science.org/doi/10.1126/science.ael3828
